Showing 1941-1950 of 2105 results for "".
- Potential Pediatric Use of New Migraine Therapieshttps://practicalneurology.com/news/potential-pediatric-use-of-new-migraine-therapies/2469437/Over the past 10 years multiple new treatments have been approved for use in adults. However, there has been little improvement in treatments specifically indicated for treatment of migraine in children, and very little data on the effects of these medications in children are available. At the Vi
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
- FDA Approves Lacosamide for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Usehttps://practicalneurology.com/news/fda-approves-lacosamide-for-primary-generalized-tonic-clonic-seizures-and-expanded-pediatric-use/2469432/The Food and Drug Administration (FDA) has approved lacosamide (Vimpat; UCB, Atlanta, GA) as adjunctive therapy for primary generalized tonic-clonic seizures (PGTCS) in children age 4 years or more and lacosamide injection for intravenous use. Results from a phase 3 study (
- Posttraumatic Stress Disorder Symptoms Increase Over Time After Concussionhttps://practicalneurology.com/news/over-time-the-effects-of-concussions-may-evolve-in-veterans/2469426/A study published in Neurology, suggest concussion (mild traumatic brain injury [mTBI]) symptoms can last as long as 5 years and evolve over time. The study evaluated and compared veterans (n=281) with an
- FDA Clears IND Application of Gene Therapy for Tay-Sachs and Sandhoff Diseaseshttps://practicalneurology.com/news/fda-clears-ind-application-of-gene-therapy-for-tay-sachs-and-sandhoff-diseases/2469420/The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a registrational study of adeno-associated viral (AAV) vector gene therapy (AXO-AAV-GM2; Axovant Gene Therapies, New York, NY) to treat individuals with Tay-Sachs disease and Sandhoff dis
- Society of Vascular and Interventional Neurology Launches Stroke Awareness Campaignhttps://practicalneurology.com/news/society-of-vascular-and-interventional-neurology-launches-stroke-awareness-campaign/2469413/The Society of Vascular and Interventional Neurology (SVIN) global campaign, Mission Thrombectomy 2020 (MT2020) has published a white paper, Mechanical Thrombectomy for Acute Stroke. Building Thrombectomy Systems of Care in Your Region: Why and How. The white paper is targeted towards health poli
- FDA Clears Trigeminal Nerve Stimulator Migraine Treatment for Use Without Prescriptionhttps://practicalneurology.com/news/fda-clears-trigeminal-nerve-stimulator-migraine-treatment-for-use-without-prescription/2469399/The Food and Drug Administration (FDA) has cleared the external trigeminal nerve stimulator (Cefaly Dual; Cefaly Technology, New York, NY ) for the acute and preventative migraine treatment in individuals age 18 years or more without a prescription. Initial purchase of the device
- Gene Therapy Improves ON Time for Individuals With Parkinson Disease in Phase 3 Trialhttps://practicalneurology.com/news/gene-therapy-improves-on-time-for-individuals-with-parkinson-disease-in-phase-3-trial/2469394/The 6-month follow-up data of a phase 2 study of a .4 x 107 TU dose of gene therapy (AXO-Lenti-PD; Axovant Gene Therapies, New York, NY) for Parkinson disease (PD) treatment showed the gene therapy improved ON time by more than 2-hours. The therapy is delivered to the putamin in a neurosurgi
- Soticlestat in Rare Epilepsies CDKL5 Deficiency and Dup15q Syndrome Phase 2 Clinical Trialshttps://practicalneurology.com/news/soticlestat-in-rare-epilepsies-cdkl5-deficiency-and-dup15q-syndrome-phase-2-clinical-trials/2469390/In the ARCADE (NCT03694275) and ENDYMION (NCT03635073) studies of soticlestat (OV935/TAK-935, Ovid Therapeutics, New York, NY) seizure frequency in individuals with CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) decreased. The combined data from ARCADE and ENDYMION studies
- Risdiplam Improves Motor Function in Infants with Type 1 SMAhttps://practicalneurology.com/news/risdiplam-improves-motor-function-in-infants-with-type-1-sma/2469388/In the 2-year pivotal FIREFISH study (NCT02913482) of risdiplam (Evrysdi; Genentech, San Francisco, CA), infants with symptomatic type 1 spinal muscular atrophy (SMA) who were treated with risdiplam at age 2 to 7 months continued to improve and achieve motor milestones. Of the 21 partic